<?xml version="1.0" encoding="UTF-8"?>
<p id="Par30">Additive approach by either serial vaccination or combined vaccination with multiple antigenic types has been successfully employed to produce pneumococcal conjugate vaccines (13 different antigens) and human papillomavirus vaccines (up to nine different antigens), which can elicit accumulated responses with non-overlapping specificities. For influenza vaccines, admixture of multivalent influenza vaccines may result in antigenic competition and eventually lead to loss of efficacy for one or more components (Kanekiyo 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR50">2019</xref>). Moreover, broad immunity has not been achieved by serial immunization with conventional flu vaccines (Belongia 
 <italic>et al.</italic>
 <xref ref-type="bibr" rid="CR7">2017</xref>).
</p>
